Investment
Features
FeesSafety
Academy
More
Pluang+

Compare InMode Ltd (INMD) vs UiPath Inc (PATH) Price & Performance

InMode LtdTrade
UiPath IncTrade

Price performance (Past 24H)

Key statistics

InMode Ltd vs UiPath Inc — how do they compare? InMode Ltd trades at $15.16 (market cap $873.13M), while UiPath Inc trades at $15.65 (market cap $8.08B). The key difference: UiPath Inc is far larger — about 9.3× InMode Ltd's market cap. Which is the better fit depends on your goals.

INMDPATH
Market Cap
$873.13M$8.08B
Sector
TechnologyTechnology
52-Week High
$16.62$19.29
52-Week Low
$12.76$9.38
Enterprise Value
$376.47M$6.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

InMode Ltd

InMode (INMD) trades at $15.31, up 1.26% with a bullish technical outlook. The stock shows strong profitability with 76.52% gross margins and 20.69% net income margin, though 2026 earnings guidance suggests margin compression. Recent developments include an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder activism. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus is divided between Buy and Hold ratings.

The investment case balances attractive valuation metrics (P/E 12.55, EV/EBITDA 5.39) against execution risks and shareholder disputes. Near-term catalysts include the Q3 2026 earnings report and potential acquisition developments. Key risks involve competitive pressures in medical aesthetics and ongoing securities investigations that could impact investor confidence.

UiPath Inc

UiPath (PATH) trades at $15.05, up 7.5% amid an AI stock rally, with technical indicators showing bullish momentum despite an overbought RSI. The company demonstrates strong revenue growth, improving from $892M in 2022 to $1.43B in 2025, with net income turning positive in 2026. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beating estimates. Analyst sentiment remains cautious with a $13.33 consensus target below current price.

PATH offers exposure to enterprise automation growth with improving profitability, but faces execution risks and competitive pressures. The stock trades at premium valuations (P/E 25.08, P/S 4.86) while cash flow trends show improvement from negative $182M in 2025 to projected negative $67M in 2026. Key risks include AI competition and software spending volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About InMode Ltd

InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.

Read more on INMD

About UiPath Inc

UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.

Read more on PATH